Latest total revenue for CCEL: $31M, below the Healthcare sector average of $110B.
Get informed when a big investor buys or sells
+ FollowAs of May 2026
Trailing 12 months ending May 2026
Cryo-Cell International posts a total revenue of $31M as of May 2026. That compares with $32M in the prior-year period — down 2.7% year over year. That is below the Healthcare sector average of $110B. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.
In the prior comparable period, Cryo-Cell International's total revenue was $32M. The latest reading is $31M — a 2.7% year-over-year decrease (period ending May 2026). Use the history and growth charts on this page for a longer lookback.
For Healthcare stocks, a total revenue near $110B is typical. Cryo-Cell International's $31M is lower that level. That is roughly 100.0% below the sector mean. Whether that is a warning or an opportunity depends on growth outlook and other fundamentals shown elsewhere on Stockcircle.
Total Revenue is one piece of Cryo-Cell International's financial statement story. At $31M, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.
Context for CCEL's total revenue usually means three checks: (1) trend versus prior periods, (2) level versus peers (average $110B), and (3) consistency with growth and profitability. This page covers the first two; Cryo-Cell International's other metric pages and overview cover the third.